Oklahoma Cancer Specialists and Research Institute

Tulsa, Oklahoma 74146

4 studies enrolling now · 20 studies all time

What they study most

ARID1A Gene Mutation, Advanced Solid Tumor, Autoimmune Diseases, Blood Coagulation Disorder, Blood Platelet Disorder, Breast Cancer, Complete Response, Cutaneous Melanoma, Endometrial Cancer, Epithelial Ovarian Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer, FIGO Stage III-IV

Studies at this site

• A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer — Recruiting now
• GEMINI-NSCLC: NSCLC Biomarker Study — Recruiting now
• BostonGene and Exigent Genomic INsight Study — Recruiting now
• Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer — Recruiting now
• A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer — Stopped early
• A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) — Running, not enrolling
• Roll-over Study to Allow Continued Access to Ribociclib — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) — Running, not enrolling
• Abemaciclib and Letrozole to Treat Endometrial Cancer — Running, not enrolling
• A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer — Completed
• The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP) — Withdrawn before enrolling
• Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma — Running, not enrolling
• A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression — Completed
• A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy — Running, not enrolling
• LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib — Completed
• Prospective Clinicogenomic Program — Completed
• A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer — Completed
• A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes — Stopped early
• PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma — Stopped early
• A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM — Stopped early